ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company developing treatments for mental health disorders. Its lead compounds include PCN-101, a subcutaneous R-ketamine for treatment-resistant depression; RL-007, a modulator for cognitive impairment in schizophrenia; DMX-1002, an oral ibogaine for opioid use disorder; GRX-917, an oral deuterated etifoxine for generalized anxiety disorder; and NN-101, an intranasal N-acetylcysteine for mild traumatic brain injuries. Other candidates include VLS-01 for depression and EMP-01 for PTSD. The ATAI average annual return since 2021 is shown above.
The Average Annual Return on the ATAI average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ATAI average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ATAI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|